We next used the VEGFA inhibitor bevacizumab30, with no additional VEGF (as the AML cells express it already), and the IL5RA inhibitor benralizumab31 with or without exogenous IL-5, to test whether the inhibitors would abrogate growth stimulation. Here, VEGFA is linked to acute myeloid leukemia.